Circulating Adaptive Immune Cells Expressing the Gut Homing Marker $\alpha 4\beta 7$ Integrin Are Decreased in COVID-19

Tanja M. Müller1, Emily Becker1, Maximilian Wiendl1, Lisa Lou Schulze1, Caroline Voskens2, Simon Völkl3, Andreas E. Kremer1, Markus F. Neurath1 and Sebastian Zundler1*

1 Department of Medicine 1 and Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 2 Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 3 Department of Internal Medicine 5, Hematology and Clinical Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Background: Infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a wide range of symptoms including gastrointestinal manifestations, and intestinal epithelial cells are a target of the virus. However, it is unknown how the intestinal immune system contributes to systemic immune responses in coronavirus disease 2019 (COVID-19).

Methods: We characterized peripheral blood lymphocytes from patients with active COVID-19 and convalescent patients as well as healthy controls by flow cytometry.

Results: The frequency and absolute number of circulating memory T and B cells expressing the gut homing integrin $\alpha 4\beta 7$ integrin was reduced during COVID-19, whether gastrointestinal symptoms were present or not. While total IgA-expressing B cells were increased, gut-imprinted B cells with IgA expression were stable.

Conclusion: COVID-19 is associated with a decrease in circulating adaptive immune cells expressing the key gut homing marker $\alpha 4\beta 7$ suggesting that these cells are preferentially recruited to extra-intestinal tissues independently of $\alpha 4\beta 7$ or that the systemic immune response against SARS-CoV-2 is at least numerically dominated by extraintestinal, particularly pulmonary, immune cell priming.

Keywords: COVID-19, SARS-CoV-2 infection, T cell trafficking, integrins, gut homing

Abbreviations: CD, cluster of differentiation; COVID-19, coronavirus disease 2019; DCs, dendritic cells; GALT, gut-associated lymphoid tissue; MAdCAM-1, mucosal addressin vascular cell adhesion molecule 1; PD-1, programmed cell death protein 1; PBMCs, peripheral blood mononuclear cells; RALDH, retinaldehyde dehydrogenase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SEM, standard error of the mean; VDZ, vedolizumab.
INTRODUCTION

The emergence of SARS-CoV-2 in late 2019 (1) has led to a global pandemic that is still far from being under control in many parts of the world. The disease caused by SARS-CoV-2 has been termed COVID-19, which is typically characterized by pneumonia potentially manifesting as fatal respiratory distress syndrome (2). However, it has already been described that a subgroup of patients with COVID-19 also shows gastrointestinal symptoms like diarrhea or vomiting (2–6) and SARS-CoV-2 RNA is frequently detected in the feces of COVID-19 patients (7). Consistently, productive infection of enterocytes in the human gut has been demonstrated (8). Mechanistically, this observation could be linked to the expression of angiotensin-converting enzyme 2 (ACE2), which serves as the entry receptor for the spike protein of SARS-CoV-2 (9), not only in the lung, but also in the digestive tract (10, 11).

As the organ with the largest surface of the body, the gastrointestinal tract faces the challenge to allow absorption of nutrients, vitamins and minerals, while protecting against potentially harmful luminal microbiota or toxic products (12). Thus, a complex immune system has established in the gut including the secondary lymphoid organs of the gut-associated lymphoid tissue (GALT) as well as immune cells in the lamina propria of the intestinal mucosa (13). A hallmark and exclusive feature of immune cell priming in the GALT is that dendritic cells (DCs) expressing the enzyme retinaldehyde dehydrogenase (RALDH) metabolize nutritional vitamin A to retinoic acid. This induces the expression of the gut homing integrin α4β7 and the chemokine receptor CCR9 on T cells receiving antigenic stimulation from these DCs (14–16) and offers the opportunity to specifically track lymphocytes imprinted in the intestine. Moreover, GPR15 has been described to be specifically expressed on T lymphocytes homing to the large intestine (17, 18).

The α4β7 integrin specifically binds to mucosal vascular addressin cell adhesion molecule (MAdCAM)-1 (19, 20), which is virtually exclusively expressed on high endothelial venules in the gastrointestinal tract (21). Hence, upon recirculation, memory T cells primed within the GALT dispose of a particular signature to re-enter intestinal tissue or GALT. Moreover, retinoic acid generated by intestinal DCs has been shown to promote IgA-secreting B cells, at least partly by inducing an isotype switch towards IgA (22, 23). Thus, intestinal infection with SARS-CoV-2 might lead to the induction of virus-specific T cells with a gut-homing signature and IgA-producing B cells in the intestine. Importantly, IgA is present on surfaces and participates in upholding mucosal immunity. IgA produced by B cells shaped in the gut might therefore also lead to cross-protection of the mucosal surface of the respiratory tract and, consistently, oral vaccination strategies against SARS-CoV-2 have been advocated and are under development (24).

We therefore set out to investigate, whether infection with SARS-CoV-2 leads to systemic signs of virus-associated intestinal T and B cell immunity in the circulation. We show that in patients with COVID-19 α4β7-expressing memory T cells are reduced compared with healthy controls even in patients with intestinal symptoms, while IgA-producing B cells are stable. However, these do not seem to originate from the gut, suggesting that gut-imprinted immune cells are eliminated from the circulation or that immune responses generated at other sites of virus entry are dominating circulating immune cell profiles in COVID-19.

METHODS

Patient Cohort

Blood for PBMC isolation was collected following informed written consent at the University Hospital Erlangen. Hospitalized patients with active SARS-CoV-2 infection (n = 110), recovered patients presenting to the Department of Transfusion Medicine (n = 35) and healthy donors (n = 28) were included.

Clinical data of COVID-19 patients were retrieved from an internal database. Clinical data of COVID-19 patients and healthy donors are summarized in Table 1, clinical data for the recovered patients are not available. Blood collection was approved by the Ethics Committee of the Friedrich-Alexander University Erlangen-Nuremberg (174_20B).

PBMC Isolation and Flow Cytometry

Human peripheral blood mononuclear cells (PBMCs) were isolated by standard density gradient centrifugation with Ficoll Paque (GE) or Lymphocyte Separation Medium (Anprotec) and stained with the following antibodies:

- CD3-APC (HIT3a, BioLegend), CD3-BV605™ (OKT3, BioLegend), CD4-APC-Vio770 (VIT4, Miltenyi Biotec), CD4-PerCP/Cy5.5 (OKT4, BioLegend), CD8a-PerCP/Cy5.5 (RPA-T8, BioLegend), CD19-VioBlue (LT19, Miltenyi Biotec), CD45RO-BV510™ (UCHL1, BioLegend), CD69-PE/DAZZLE™ 594 (FN50; BioLegend), CD154-FITC (24-31, BioLegend), CCR9-PE/Cy7 (L053E8, BioLegend) Integrin α4-PE/Cy7 (9F10, BioLegend), Integrin α4-VioBlue (MZ18-24A9, Miltenyi Biotec) Integrin β1-PE (TS2/16, BioLegend), Integrin β7-BV605™ (FIB504, BioLegend), GPR15-PE (SA302A10, BioLegend), IgA-FITC (ab97219, abcam), Vedolizumab (Takeda Pharmaceuticals) labeled with Alexa Fluor® 488 (Invitrogen) or Alexa Fluor® 647 (Invitrogen).

Table 1: Baseline characteristics of patients with SARS-CoV-2 infection and healthy controls.

|                        | Healthy controls | COVID-19 patients |
|------------------------|------------------|-------------------|
| Number                 | 28               | 110               |
| Male [%]               | 28               | 64                |
| Female [%]             | 72               | 36                |
| Ø Age in years         | 28.8             | 63.5              |
| Diarrhea               |                  | 7                 |
| Course of disease      | Mild             |                   |
|                        | Severe           | 17                |
| Pre-existing cardiovascular disease | /               | 17                |
PBMCs were washed for 5 min in PBS at 300x g and 4°C and fixed overnight at 4°C using the Foxp3 transcription buffer staining kit (Thermo Fisher). Subsequently, PBMCs were washed, resuspended in 200µl FACS buffer (1% FBS, 2mM EDTA in PBS) and analyzed on a MacsQuant16 instrument (Miltenyi).

In some experiments, full blood was stained for flow cytometry as follows: 200µl peripheral whole blood was incubated for 15 minutes with 2ml Lysing Buffer (BD Pharm Lyse™, BD Biosciences) to lyse red blood cells. Samples were washed and subjected to antibody staining as described above. After fixation and washing of the samples exactly 200µl FACS buffer was added and the samples were analyzed on a MacsQuant16 instrument.

**SARS-CoV-2 Specific T Cell Stimulation**

SARS-CoV-2-specific T cell response was analyzed by stimulating PBMCs from COVID-19 patients and healthy controls with a pool of peptides covering the immunodominant sequence domains of the surface glycoprotein of SARS-CoV-2 (PepTivator of peptides covering the immunodominant sequence domains of SARS-CoV-2 Prot_S-research grade, Miltenyi Biotec) for 5 hours according to the manufactures instructions. Subsequently, stimulated PBMCs were stained with antibodies as described above and analyzed on a MacsQuant16 instrument. SARS-CoV-2-specific T cells were detected with antibodies against CD69 and CD154.

**Statistical Analysis**

GraphPad Prism (GraphPad Software, Inc.) was used to perform statistical analyses.

Results are shown as scatter dot plots with individual data points. Center values and error bars represent mean and standard error of the mean (SEM).

Normal distribution was tested using Shapiro-Wilk test. When comparing two groups, statistical differences were tested using student's T test for data with normal distribution or Mann Whitney U test for data without a normal distribution. When comparing more than two groups, statistical differences were tested using one-way ANOVA with Tukey’s multiple comparison for data with a normal distribution or Kruskal-Wallis test with Dunn’s multiple comparison for data without a normal distribution. For correlation analyses, Spearman correlation was performed and a regression line is indicated. An α value of p < 0.05 was defined as statistically significant.

Significance levels are indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001).

**RESULTS**

**α4β7 Integrin-Expressing Memory T Cells Are Decreased in COVID-19**

We characterized T and B cells in the peripheral blood from a cohort of 80 patients with active COVID-19 and 35 patients recovered from COVID-19 as well as 18 healthy controls by flow cytometry of PBMCs. Clinical information on the patients is provided in Table 1. The overall frequency of CD3⁺ and CD3⁺CD4⁺ T cells was similar in patients with active or previous COVID-19 and in controls (Supplementary Figures 1A, B). Peripheral CD45RO⁺ memory CD4⁺ T cell and CD3⁺CD19⁺ B cell frequencies in patients with active or after COVID-19 were numerically, but not significantly increased compared with healthy donors (Supplementary Figures 1C, D).

To explore the presence of T cells primed in the intestine during SARS-CoV-2 infection, we analyzed the expression of α4β7 integrin on T cells in the peripheral blood. Interestingly, the portion of CD3⁺CD4⁺ T cells expressing α4β7 was substantially reduced in previous COVID-19 patients compared to healthy controls (Figure 1A). On CD3⁺CD4⁺CD45RO⁺ memory T cells, we observed a clear reduction of α4β7 expression in patients with active COVID-19. However, expression increased in the recovery phase, while still being lower than in controls (Figure 1B). Interestingly, there was no difference between patients with mild and severe course of COVID-19 as well as between patients with and without diarrhea (Figure 1C and Supplementary Figure 2). Even when relating the expression of α4β7 on CD45RO⁺ memory T cells to total CD3⁺CD4⁺ T cells, frequencies were decreased in COVID-19 patients compared to healthy controls (Figure 1D).

Since these data were only indicating relative expression and not absolute cell numbers, and did not exclude the possibility of co-expression of α4 and β7 integrin without heterodimerization, we sought to validate our findings in an additional patient cohort. Here, we stained full blood samples and used fluorescently labeled vedolizumab, a monoclonal antibody specific for the α4β7 heterodimer used for the therapy of inflammatory bowel diseases (25). In accordance with previous literature marked lymphopenia was present in COVID-19 patients (Supplementary Figure 3). Corroborating our previous observations, the fraction as well as the absolute number of CD3⁺CD4⁺CD45RO⁺ T cells staining positive for vedolizumab was markedly reduced in patients with COVID-19 (Figure 2A).

To estimate, in how far expression of α4β7 integrin on overall memory CD4⁺ T cells reflects α4β7 expression of SARS-CoV-2-induced memory T cells, we used a cocktail of viral epitopes to stimulate PBMCs from COVID-19 patients. Flow cytometry demonstrated that there was a high degree of correlation of α4β7 expression between these cell subsets (Figure 2B). Moreover, we compared the expression of α4β7 on SARS-CoV-2-specific CD4⁺ memory T cells from COVID-19 patients with healthy donors without SARS-CoV-2 infection that also had SARS-CoV-2-specific T cells in their peripheral blood as previously reported (26). Again, we observed a striking decrease in the expression of α4β7 on these cells in COVID-19 patients compared with controls (Figure 2C), suggesting that circulating T cells primed in the gut are reduced in hospitalized patients with acute SARS-CoV-2 infection.

**GPR15, CCR9 and α4β1 Are Not Specifically Reduced in COVID-19**

Next, we aimed to determine, whether T cells expressing gut-homing chemokine receptors are similarly reduced. Accordingly, we quantified the expression of GPR15, a receptor specifically expressed on T cells homing to the large intestine (17, 18), in full blood samples by flow cytometry. We observed no significant
change of GPR15 expression in patients with active or after COVID-19 on CD4+ memory T cells (Figure 3A).

While the fraction of CD4+ memory T cells expressing the chemokine receptor CCR9, which is associated with trafficking to the small intestine (27), was similar between patients with COVID-19 and healthy controls, their absolute numbers in the circulation were significantly reduced (Figure 3B). We therefore decided to further investigate the abundance of memory T cells expressing the integrin α4β7, which has been implicated in homing to the small intestine (28). We observed a trend towards a reduction in the frequency of CD4+ memory T cells expressing α4β7 and a significant reduction in the absolute number of these cells in the circulation (Figure 3C).

Together, these effects were largely driven by the lymphopenia present in COVID-19 patients and, thus, the data suggested that infection with SARS-CoV-2 does not affect the expression of other gut-homing markers to a similar extent as α4β7.

**Reduction of Circulating α4β7-Expressing CD8+ T Cells in COVID-19**

Since CD8+ T cells are crucially implicated in the immune response against viruses, we also explored the expression of gut-homing markers on CD8+ T cells during COVID-19. The percentage as well as the absolute number of CD3+CD8+ T cells in the peripheral blood of patients with COVID-19 was clearly reduced (Supplementary Figure 4). As in the CD4 compartment, a smaller fraction of CD8+ T cells

---

**FIGURE 1** | Frequency of α4β7+ T cells during COVID-19. (A, B) Representative (left) and quantitative (right) flow cytometry of the frequency of α4β7 integrin-expressing CD3+CD4+ T cells (A) and CD3+CD4+CD45RO+ memory T cells (B). (C) Quantitative flow cytometry of the frequency of α4β7 integrin-expressing CD3+CD4+CD45RO+ memory T cells in COVID-19 patients with mild or severe disease course (left) and with or without diarrhea (right) compared to healthy controls. (D) Quantitative flow cytometry of the frequency of α4β7 integrin-expressing CD3+CD4+CD45RO+ memory T cells expressed as frequency of CD3+CD4+ T cells. Each symbol represents an individual subject, n = 7 - 80 per group. *p < 0.05, **p < 0.01, ***p < 0.001.
cells from COVID-19 patients expressed α4β7 integrin (as indicated by positive staining for vedolizumab) compared to healthy controls. Similarly, the absolute number of these cells was substantially reduced (Figure 4A). For CCR9, the relative expression was not significantly altered, but the absolute number of CCR9-expressing circulating CD8+ T cells was reduced (Figure 4B). This was similar for α4β1, although, here, the increase in relative expression was significant, while the decrease in absolute cell numbers was not (Figure 4C).

Collectively, these observations largely recapitulated our findings for CD4+ T cells.

**IgA-Producing B Cells Without a Gut-Homing Phenotype Are Increased in Response to SARS-CoV-2**

Finally, we quantified the frequency of circulating CD19+ B cells expressing IgA. We observed a clear increase in patients with COVID-19 that persisted in the recovery phase (Figure 5A).
This was more pronounced in patients with severe disease course, but similar in patients with and without gastrointestinal symptoms (Figure 5B).

Since a gut-homing phenotype including the expression of $\alpha_4\beta_7$ integrin is also induced in B cells in the gut (23), we subsequently assessed the expression of $\alpha_4\beta_7$ on these B cells. Similar to T cells, the frequency of $\alpha_4\beta_7$-expressing B cells in patients with COVID-19 decreased and slightly re-increased in the recovery phase (Figure 5C). Interestingly, the increase in IgA-expressing B cells was not significant in the $\alpha_4^+\beta_7^+$ subset (Figure 5D), supporting the notion that circulating IgA-expressing B cells during SARS-CoV-2 infection do not predominantly originate from the gut.

Again, we tried to reproduce our findings in a second patient cohort using full blood and staining with vedolizumab to detect $\alpha_4\beta_7$ integrin. Similar to the analysis of PBMCs, $\alpha_4\beta_7$-expressing B cells were significantly lower both on relative and absolute level (Figure 5E). Moreover, we again observed a numeric increase in the fraction of IgA-expressing B cells during COVID-19. Yet, this was not the case on absolute levels (Figure 5F). Notably, the expression of IgA on $\alpha_4\beta_7^+$ B cells was also lower in COVID-19 (Figure 5G).

Taken together, also in the B cell compartment, our data indicated that immune responses originating from the intestine in COVID-19 leave rather minor traits in the circulation.

**DISCUSSION**

The immune system is critical in the pathogenesis of COVID-19 (29, 30). Mediators released by infected cells initially recruit innate immune cells to the site of infection. This is the prerequisite for the subsequent generation of adaptive immune responses by presentation of SARS-CoV-2 epitopes to naïve T and B cells in local lymph nodes and the ensuing recruitment of antigen-experienced T cells to the site of inflammation as well as the production of specific antibodies by B cells (30). These processes are considered important for the clearance of the
infection and the resolution of inflammation, but insufficient control, to the contrary, is involved in the development of acute respiratory distress syndrome and hyperinflammation in patients with severe disease course (31). Consistently, dexamethasone is an effective treatment in patients with severe COVID-19 (32).

In particular, it has been shown that T cells recognizing multiple regions of the spike, M and N protein of SARS-CoV-2 develop during COVID-19 (26, 33, 34) and that recognition of multiple epitopes is associated with milder symptoms (35). SARS-CoV-2-induced T cell immunity is maintained for at least six months and symptomatic primary infection is associated with higher levels of the persisting T cell response (36).

The lung and the gut are considered the main portals of entry for SARS-CoV-2 (37, 38). However, pulmonary manifestation dominates the clinical disease phenotype and only a subset of hospitalized patients suffers from gastrointestinal symptoms (2, 4). It is currently unclear, how infection of the lung alveolar and the intestinal epithelium contribute to the generation of the systemic immune response against SARS-CoV-2. Importantly, memory T and B cells primed in the gut are characterized by the expression of the gut-homing marker α4β7 integrin (20, 23). We therefore decided to study circulating T and B cell responses in hospitalized patients with COVID-19 to determine the contribution of SARS-CoV-2-associated intestinal lymphocyte imprinting based on gut-homing phenotypes.

In conclusion, our data show that adaptive immune cells expressing the gut homing integrin α4β7 are reduced in the peripheral blood of patients with COVID-19. It is very likely that α4β7 expression on memory lymphocytes is reflecting priming following antigen contact in the GALT, where the exclusive production of retinoic acid by DCs induces α4β7 integrin expression and imprints a gut homing phenotype. Thus, our data suggest that cells having received intestinal antigenic cues in the GALT are reduced in the peripheral blood during COVID-19. It is essential to keep in mind that this does not indicate that the cells have been in the gut tissue itself or that they will later home to the gut tissue.

Two main interpretations for this observation are conceivable: (1) α4β7-expressing lymphocytes are preferentially recruited from the circulation to peripheral tissues or (2) predominant (re-)
circulation of lymphocytes not expressing α4β7 leads to a “dilution” of gut-imprinted cells.

The former option goes along with the clinical hallmark of lymphopenia in COVID-19, which is thought to arise from lymphocyte recruitment to tissues (31). Since CD4+ and CD8+ T and B cell frequencies expressing α4β7 decreased regardless of the presence of diarrhea as a symptom indicative of gastrointestinal involvement and fecal detection of virus
RNA (39, 40), it is unlikely that such recruitment happens to the gut (30). However, it can still not be ruled out that α4β7+ cells might co-express other homing markers leading to their α4β7-independent uptake in other tissues or that they are eliminated from the blood by other mechanisms under inflammatory conditions. In this case, α4β7 expression might mark a lymphocyte population with particular pathogenetic relevance.

The second explanation would suggest that adaptive immune cells primed in the gut do at least numerically not play a major role for the systemic immune response against SARS-CoV-2 in COVID-19 even in patients, in which gastrointestinal involvement is likely. This would also be in line with the finding that IgA-expressing B cells with a gut homing phenotype did not contribute to the overall increase in IgA-expressing B cells observed in COVID-19 patients. One possible explanation might be that intestinal SARS-CoV-2 infection leads to the predominant generation of local immunity characterized by tissue-resident memory T cells (41) and, interestingly, a large part of intestinal T cells have a resident phenotype (42).

If this second interpretation is true, our findings might be interesting in the context of the ongoing efforts to develop efficient vaccines against SARS-CoV-2. While most candidate vaccines are designed as injections, some oral vaccines are also under development (e.g., VXA-CoV2-1). It has previously been shown for adenovirus subtypes and influenza that oral vaccines can also protect from pulmonary infections (43–45). Moreover, mucosal administration has been proposed to be more effective in inducing protective mucosal immunity (including the lung) than systemic application (46). It would then have to be doubted that this is similarly the case in COVID-19 in view of reduced gut-imprinted immunity in the circulation during active infection with the virus.

A limitation of our study is that most of our experiments did not assess SARS-CoV-2-specific T cells. However, our observations following virus-specific stimulation suggest that there is a clear correlation of α4β7 expression on overall memory CD4+ T cells with expression on SARS-CoV-2-specific memory CD4+ T cells. Moreover, the consistent alterations we observed during active infection and recovery in different patients as well as in a second patient cohort, strongly suggest that the effects are COVID-19-associated. It should also be noted that a certain difference in the age of our control group compared with the COVID-19 patients exists and age-related effects on integrin expression cannot be completely ruled out.

While lymphopenia is a hallmark of COVID-19 and has repeatedly been reported, lymphocyte subset analyses in the peripheral blood of patients with COVID-19 have only rarely been performed. In a cohort of 44 patients, Qin et al. reported reduced memory T cell levels in patients with severe compared to mild COVID-19, which were, however, still in the normal range (47). Similarly, Sekine et al. also observed decreased frequencies of memory T cells in patients with COVID-19, more in severe than in mild disease, and described the upregulation of markers such as CD38, CD69 or PD-1 (48). However, data on the expression of gut-homing markers in the context of SARS-CoV-2 infection have so far been missing.

Taken together, our findings suggest that gut-imprinted adaptive immune cells are eliminated from the circulation during COVID-19 hinting at a potential central role in its pathogenesis or that – in line with clinical symptoms – not the intestinal immune system, but other sites such as the lung dominate the shaping of systemic immune responses to SARS-CoV-2.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics Committee of the Friedrich-Alexander University Erlangen-Nuremberg (174_20B). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

TM performed the experiments and analyzed the clinical data. TM, MN, and SZ designed the research. TM, EB, MW, LS, CV, SV, AK, MN, and SZ contributed samples or protocols and analyzed and interpreted the data. TM and SZ drafted the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

German Research Foundation (DFG, ZU 377/4-1 to SZ, TRR241 TP C04 to CV and MFN), Interdisciplinary Center for Clinical Research (IZKF) of the University Erlangen-Nuremberg (J63, A84 to SZ), Wilhelm Sander-Stiftung (2020.045.1 to SV), “Bayerische Forschungsförderung” (SV), Bavarian State Ministry for Sciences and Art (TP-10 and TP-11 to AK), and National research network for University Medicine (NUM to AK).

**ACKNOWLEDGMENTS**

The research of MN and SZ was supported by the Interdisciplinary Center for Clinical Research (IZKF) and the ELAN program of the University Erlangen-Nuremberg, the Else Kröner-Fresenius-Stiftung, the Fritz Bender-Stiftung, the Dr. Robert Pfleger Stiftung, the Litwin IBD Pioneers Initiative of the Crohn’s and Colitis Foundation of America (CCFA), the Kenneth Rainin Foundation, the Ernst Jung-Stiftung for Science and Research, the German Crohn’s and Colitis Foundation (DCCV) and the German Research Foundation (DFG) through individual grants.
T cells among lymphoid cells selected based on forward and sideward scatter, recovered patients compared to healthy controls. Representative (left) and quantitative (right) flow cytometry of the frequency of CD3+ (A) and CD3+CD4+ (B) T cells among lymphoid cells selected based on forward and sideward scatter, CD45RO+ cells among CD3+CD4+ T cells (C) and CD3+CD19+ B cells (D) among lymphoid cells. Each symbol represents an individual subject, n = 18–80 per group.

**Supplementary Figure 2** | Quantitative flow cytometry of the expression of the indicated markers stratified according to clinical parameters of COVID-19 patients. (A) Frequency of ex4[β+] and GPR15+ cells among CD3+CD4+ T cells according to oxygen saturation. (B) Frequency of ex4β7 integrin-expressing CD3+CD4+CD45RO+ memory T cells according to respiratory rate and heart rate. (C) Frequency of IgA-expressing CD3+CD19+ B cells according to respiratory rate and heart rate. Each symbol represents an individual subject, n = 8–18 per group.

**Supplementary Figure 3** | Lymphocyte subsets in whole blood samples from patients with COVID-19 and healthy controls. Quantitative flow cytometry of the frequency (left) and absolute cell numbers (right) of CD3+ (A), CD3+CD4+ (B) T cells among lymphoid cells selected based on forward and sideward scatter, CD45RO+ cells among CD3+CD4+ T cells (C) and CD3+CD19+ B cells (D) among lymphoid cells. Each symbol represents an individual subject, n = 10–31 per group.

**Supplementary Figure 4** | Lymphocyte subsets in whole blood samples from patients with COVID-19 and healthy controls. Representative (left) and quantitative (right) flow cytometry of the frequency and absolute cell numbers of CD8+CD8+ T cells among lymphoid cells selected based on forward and sideward scatter. Each symbol represents an individual subject, n = 10–31 per group.

**REFERENCES**

1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature* (2020) 579:265–9. doi: 10.1038/s41586-020-2008-3
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med* (2020) 382(13):1199–207. doi: 10.1056/NEJMoa2001316
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 314 Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* (2020) 323:1061–9. doi: 10.1001/jama.2020.1585
5. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical, and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut* (2020) 69:1002–9. doi: 10.1136/gutjnl-2020-320926
6. Suresh Kumar VC, Mukherjee S, Harne PS, Subedi A, Ganapathy MK, Pathipati VS, et al. Novelty in the gut: a systematic review and meta-analysis of colon T cell homing receptor GPR15 in inflammatory bowel disease. *Cell Mol Immunol* (2015) 12:207. doi: 10.1038/cmi.2015.76
7. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. *Gastroenterology* (2020) 158:1831–3.e3. doi: 10.1053/j.gastro.2020.02.055
8. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. *Science* (2020) 369:50–4. doi: 10.1126/science.abc1669
9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Prostate Inhibitor. *Cell* (2020) 181:271–280.e8. doi: 10.1016/j.cell.2020.02.052
10. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue acidification of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* (2004) 205:631–7. doi: 10.1002/path.1570
11. Zhang H, Li H-B, Lyu J-R, Lei X-M, Li W, Wu G, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. *Int J Infect Dis* (2020) 96:19–24. doi: 10.1016/j.ijid.2020.04.027
12. Zundler S, Neurath MF. Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders. *Immunol Rev* (2017) 278:263–76. doi: 10.1111/imr.12544
13. Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. *Nat Immunol* (2019) 20:970–9. doi: 10.1038/s41590-019-0415-0
14. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song S-Y. Retinoic acid imprints gut-homing specificity on T cells. *Immunity* (2004) 21:527–38. doi: 10.1016/j.immuni.2004.08.011
15. Molenar R, Knippenberg M, Gouverse LL, Neurath MF. Immune cell trafficking and species-specific expression of SARS-CoV-2. *Science* (2020) 369:507–10. doi: 10.1126/science.abb6606
16. Bakdash G, Vogelpoel LT, van Capel TM, Laarman AG, et al. Retinoic acid imprints gut-homing specificity on T cells. *Immunology* (2019) 161:257–64. doi: 10.1111/immu.13672
17. Kim SV, Dvjakovic S, Kwak C, Wang P, Lin WM, Otto M, et al. Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells. *Mucosal Immunol* (2015) 8:265–78. doi: 10.1038/mi.2014.64
18. Dvir T, Peretz M, Rosenzweig A, Klimo R, et al. Retinoic acid imprints gut-homing specificity on T cells. *Immunology* (2016) 158:1831–7. doi: 10.1111/imj.12828
19. Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and species-specific expression of SARS-CoV-2. *Science* (2020) 369:507–10. doi: 10.1126/science.abb6606
20. Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. *Gut* (2019) 68:6088–700. doi: 10.1136/gutjnl-2018-317977
21. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. *Immunity* (2019) 51:971–81. doi: 10.1016/j.immuni.2019.06.005
22. Seo G-Y, Jang Y-S, Kim H-A, Lee M-R, Park M-H, Park S-R, et al. Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells. *Mucosal Immunol* (2015) 8:265–78. doi: 10.1038/mi.2014.64
23. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. *Science* (2006) 314:1157–60. doi: 10.1126/science.1132742

ZU 377/4-1 and the Collaborative Research Centers TRR241, 643, 796 and 1181. The present work was performed in partial fulfillment of the requirements for obtaining the degree “Dr. rer. biol. hum.” for SZ. The authors thank Julia Derdaul, Julia Markcs, Julia Schuster, Dorothea Dziony, Alina Bauer, Dorothea Gebhardt and Alina Kämpfl for excellent technical assistance. We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) within the funding program Open Access Publishing.
24. Mehan A, Venkatesh A, Girish M. COVID-19: should oral vaccination strategies be given more consideration? Ther Adv Vaccines Immunother (2020) 5:1553535820946503.
25. Mühl I, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, et al. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol (2021) 21:33. doi: 10.1186/s12870-021-01604-z
26. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature (2020) 584:457–62. doi: 10.1038/s41586-020-2550-z
27. Stenstad H, Ericsson A, Johansson-Lindbom B, Svensson M, Marsal J, Mack M, et al. Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine. Blood (2006) 107:3447–54. doi: 10.1182/blood-2005-07-2860
28. Zundler S, Fischer A, Schillinger D, Binder MT, Atreya R, Rath T, et al. The α4β7 Homing Pathway Is Essential for Ileal Homing of Crohn’s Disease Effector T Cells. In Vivo. Inflamm Bowel Dis (2017) 23:739–91. doi: 10.1097/MIB.0000000000001029
29. Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci (2020) 256:117990. doi: 10.1016/j.lfs.2020.117990
30. Tay MZ, Poh CM, Régnier L, MacArt PA. N. LFP. The trinity of COVID-19: immuno, inflammation and intervention. Nat Rev Immunol (2020) 20 (6):363–74. doi: 10.1038/s41577-020-0311-8
31. Neurath MF. COVID-19 and immunomodulation in IBD. Gut (2020) 69:1335–42. doi: 10.1136/gutjnl-2020-321269
32. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Anker SD, Bellasis L, et al. Dexamethasone in Hospitalized Patients with COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol (2020) 18:1663–72. doi: 10.1016/j.cgh.2020.04.001
33. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-induced CD4+ T cell immunity in healthy donors and patients with COVID-19. Nature (2020) 587:270–4. doi: 10.1038/s41586-020-2598-9
34. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell (2020) 181:1489. doi: 10.1016/j.cell.2020.05.015
35. Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol (2020) (1):74–85. doi: 10.1038/s41590-018-0298-5
36. Zuo J, Dowell A, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. bioRxiv (2020). doi: 10.1101/2020.11.01.362319
37. D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol (2020) 18:1663–72. doi: 10.1016/j.cgh.2020.04.001
38. Patankar JV, Chiriac M, Lehmann M, Kühl AA, Atreya R, Becker C. The SARS-CoV-2 attachment receptor ACE2 is decreased in Crohn’s disease and regulated by microbial and inflammatory signaling. Gastroenterology (2020) 160(3):925–8.e4. doi: 10.1053/j.gastro.2020.10.021
39. Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, et al. Diarrhea Is Associated With Prolonged Symptoms and Viral Correlation in Coronavirus Disease 2019. Clin Gastroenterol Hepatol (2020) 18:1753–9.e2. doi: 10.1016/j.cgh.2020.04.030
40. Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol (2020) 115(6):916–23. doi: 10.14309/ajg.0000000000006664
41. Karlsson AC, Humbert M, Buggert M. The known unknowns of T cell immunity to COVID-19. Sci Immunol (2020) 5(53):eaee8063. doi: 10.1126/sciimmunol.abe8063
42. Zundler S, Becker E, Spocinska M, Slawik M, Parga-Vidal L, Stark R, et al. Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nat Immunol (2019) 20:288–300. doi: 10.1038/s41590-018-0298-5
43. Chen S, Tian X. Vaccine development for human mastadendovirus. J Thorac Dis (2018) 10:S2280–94. doi: 10.21037/jtd.2018.03.168
44. Liebowitz D, Gottlieb K, Kolhatkar NS, Garg SJ, Asher JM, Nazareno J, et al. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. Lancet Infect Dis (2020) 20:435–44. doi: 10.1016/S1473-3099(19)30584-5
45. Choudhury A, Mathena J, Albano JD, Vacovnicek M, Collins I. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine (2016) 34:4558–64. doi: 10.1016/j.vaccine.2016.07.033
46. Goffin E, Javoux J, Destexhe E, Prettio CD, Spindler KR, Machiels B, et al. Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract. J Virol (2019) 93(13):e00237-19. doi: 10.1128/JVI.00237-19
47. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis (2020) 71:762–8. doi: 10.1093/cid/ciaa248
48. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell (2020) 183:158–68.e14 doi: 10.1016/j.cell.2020.08.017

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Müller, Becker, Wiendl, Schulze, Voskeris, Völkl, Kremer, Neurath and Zundler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.